Official Title:  A Pilot Study to Explore the Use of Percutaneous Spinal Stimulation in 
Participants with Multiple Sclerosis  
Study ID: [REMOVED]  
Document Date: 05 December 2023  
  ES in MS   Version 2.3 
  Revised 12/05/2023  
Page 1 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL    
A Pilot Study to Explore the Use of Percutaneous Spinal Stimulation in Participants  
with  Multiple  Sclerosis  
 
 
Principal  Investigator  
 
 
 
 
 
Co-Investigator(s) Kristin  Zhao,  Ph.D.  
Department of Physical Medicine and Rehabilitation  
Mayo  Clinic  
200 First Street SW  
Rochester,  MN 55905 
(507) 284-8942 
 
William Oliver Tobin, MBBCh, Ph.D. 
Department  of Neurology 
Mayo  Clinic  
200 First Street SW  
Rochester,  MN 55905 
(507) 538-2679 
 
Peter  Grahn, Ph.D. 
Department of Physical Medicine and Rehabilitation  
Mayo  Clinic  
200 First Street SW  
Rochester,  MN 55905 
(507) 316-5556 
 
Megan  Gill, P.T., D.P.T. 
Department of Physical Medicine and Rehabilitation  
Mayo  Clinic  
200 First Street SW  
Rochester,  MN 55905 
(507) 422-0139 
Funding  Sponsor: Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology 
Study  Product:  Abbott percutaneous trial lead for epidural  
neurostimulation  (Model 3086) 
Abbott Neuromodulation 6901 Preston Road Plano, TX  75024 
 
Ripple Nomad Neurostimulator  
Ripple Neuro  
2056 South 1100 East  
Salt Lake  City,  UT 84106  
  ES in MS   Version 2.3 
  Revised 12/05/2023  
Page 2 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL    
Abbott clinician programmer for epidural and dorsal 
root ganglion neurostimulation (Model 3874) 
Abbott Medical 
6901 Preston Road Plano, TX 75024 
 
Protocol Number:  (IRBe)  23-003967 
IDE Number:  G210292 
 
 
Initial version:   10/01/2021 ( Version  1.0) 
Revision:    02/08/2023 (Version 2.0) 
Revision:   06/13/2023 (Version 2.1) 
Revision:   06/23/2023 (Version 2.2) 
Revision:   12/05/2023 (Version 2.3)  
 
Table of Contents  
A PILOT STUDY TO EXPLORE THE USE OF PERCUTANEOUS SPINAL STIMULATION IN PARTICIPANTS  WITH  MULTIPLE 
SCLEROSIS  ......................................................................................................................................................................... 1  
REVISION :   02/08/2023  (VERSION 2.0) ......................................................................................................................... 2  
TABLE  OF CONTENTS  ......................................................................................................................................................... 2  
STUDY  SUMMARY  ........................................................................................................................................................... 5  
1 INTRODUCTION  ...................................................................................................................................................... 5  
1.1 BACKGROUND  ...................................................................................................................................................... 6  
1.2 INVESTIGATIONAL  DEVICE  ................................................................................................................................... 8  
1.3 PRECLINICAL  DATA .............................................................................................................................................. 8  
1.4 STUDY RATIONALE  AND RISK ANALYSIS  (RISKS  TO BENEFITS  RATIO ) ................................................................ 9  
1.4.2 ANTICIPATED  RISKS ............................................................................................................................................. 9  
1.4.3 POTENTIAL  BENEFITS  ......................................................................................................................................... 11 
1.5 ANTICIPATED  DURATION OF THE  CLINICAL  INVESTIGATION  .............................................................................. 11 
2 STUDY  OBJECTIVES  ............................................................................................................................................ 11 
2.1 PRIMARY  OBJECTIVE  .......................................................................................................................................... 11 
2.2 SECONDARY OBJECTIVE  ..................................................................................................................................... 11 
3 STUDY DESIGN  ...................................................................................................................................................... 11 
3.1 GENERAL  DESIGN  ............................................................................................................................................... 11 
3.2 PRIMARY  STUDY ENDPOINTS  ............................................................................................................................. 12 
3.3 PRIMARY  SAFETY  ENDPOINTS  ............................................................................................................................ 12 
4 SUBJECT  SELECTION,  ENROLLMENT  AND WITHDRAWAL  ................................................................... 13 
4.1 INCLUSION CRITERIA  .......................................................................................................................................... 13 
4.2 EXCLUSION CRITERIA ......................................................................................................................................... 13 
4.3 SUBJECT  RECRUITMENT , ENROLLMENT AND SCREENING  ................................................................................... 14 
4.4 EARLY WITHDRAWAL  OF SUBJECTS  ................................................................................................................... 14 
4.4.1 WHEN AND HOW TO WITHDRAW  SUBJECTS  ....................................................................................................... 15 
  ES in MS   Version 2.3 
  Revised 12/05/2023  
Page 3 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   4.4.2 DATA COLLECTION  AND FOLLOW -UP FOR  WITHDRAWN SUBJECTS  .................................................................... 15 
5 STUDY DEVICE  ...................................................................................................................................................... 15 
5.2 METHOD FOR  ASSIGNING  SUBJECTS  TO TREATMENT  GROUPS  ............................................................................ 15 
5.3 PREPARATION AND ADMINISTRATION /IMPLANTATION OF INVESTIGATIONAL  DEVICE  ....................................... 15 
5.4 SUBJECT  COMPLIANCE  MONITORING  ................................................................................................................. 17 
5.5 PRIOR  AND CONCOMITANT  THERAPY  ................................................................................................................. 17 
5.6 PACKAGING AND LABELING  ............................................................................................................................... 17 
5.7 MASKING /BLINDING  OF STUDY  .......................................................................................................................... 17 
5.8 RECEIVING , STORAGE , DISTRIBUTION  AND RETURN  .......................................................................................... 17 
5.8.1 RECEIPT OF INVESTIGATIONAL  DEVICES  ............................................................................................................ 17 
5.8.2 STORAGE  ............................................................................................................................................................ 18 
5.8.3 DISTRIBUTION  OF STUDY DEVICE  ....................................................................................................................... 18 
5.8.4 RETURN  OR DESTRUCTION OF STUDY DEVICE  .................................................................................................... 18 
6 STUDY  PROCEDURES  .......................................................................................................................................... 18 
6.1 SCREENING  ......................................................................................................................................................... 18 
6.2 EPIDURAL  ELECTRICAL STIMULATION (ES) ....................................................................................................... 19 
6.3 PERIOD  OF FOLLOW -UP AFTER  ES ...................................................................................................................... 20 
6.4 OUTCOME  MEASURES  ........................................................................................................................................ 20 
7 STATISTICAL PLAN  ............................................................................................................................................. 22 
7.1 SAMPLE  SIZE DETERMINATION  .......................................................................................................................... 22 
7.2 STATISTICAL  METHODS  ...................................................................................................................................... 22 
7.3 SUBJECT  POPULATION (S) FOR  ANALYSIS  ............................................................................................................ 22 
8 SAFETY  AND ADVERSE  EVENTS  ...................................................................................................................... 23 
8.1 DEFINITIONS  ....................................................................................................................................................... 23 
8.2 RECORDING OF ADVERSE  EVENTS  ...................................................................................................................... 25 
8.3 SPONSOR -INVESTIGATOR REPORTING OF UNANTICIPATED ADVERSE DEVICE EFFECTS AND  UNANTICIPATED 
PROBLEMS  ....................................................................................................................................................................... 25 
8.3.1 SPONSOR -INVESTIGATOR  REPORTING , NOTIFYING  MAYO IRB .......................................................................... 26 
8.3.2 SPONSOR -INVESTIGATOR  REPORTING : NOTIFYING THE  FDA  ............................................................................. 26 
8.4 STOPPING RULES  ................................................................................................................................................ 27 
8.5 MEDICAL  MONITORING  ...................................................................................................................................... 27 
9 DATA HANDLING  AND RECORD KEEPING  ................................................................................................... 27 
9.1 CONFIDENTIALITY  .............................................................................................................................................. 27 
9.2 SOURCE  DOCUMENTS  ......................................................................................................................................... 28 
9.3 CASE  REPORT  FORMS  ......................................................................................................................................... 28 
9.4 RECORDS  RETENTION  ......................................................................................................................................... 29 
10 STUDY MONITORING,  AUDITING,  AND INSPECTING  ................................................................................ 29 
10.1 STUDY MONITORING PLAN ................................................................................................................................ 29 
10.2 AUDITING  AND INSPECTING  ................................................................................................................................ 30 
11 ETHICAL CONSIDERATIONS  ............................................................................................................................ 30 
12 STUDY FINANCES  ................................................................................................................................................. 30 
12.1 FUNDING SOURCE  .............................................................................................................................................. 30 
12.2 CONFLICT  OF INTEREST  ...................................................................................................................................... 30 
12.3 SUBJECT  STIPENDS  OR PAYMENTS  ...................................................................................................................... 31 
13 PUBLICATION  PLAN  ............................................................................................................................................ 31 
14 REFERENCES  ......................................................................................................................................................... 31 
 
  ES in MS   Version 2.3 
  Revised 12/05/2023  
Page 4 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL    
 
 
LIST  OF ABBREVIATIONS  
 
AE Adverse  Event/Adverse  Experience  
BWS  Body  weight  support  
CFR  Code  of Federal  Regulations  
CMSAN  (Mayo  Clinic)  Center  for Multiple  Sclerosis  
and Autoimmune  Neurology  
CRF  Case  Report  Form  
DSMB  Data  and Safety  Monitoring  Board  
EDSS  Expanded  Disability  Severity  Scale  
EMG  Electromyography  
ES Epidural  electrical  spinal  stimulation  
FDA  Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
HRPO  Human  Research  Protection  Office  
IDE Investigational  Device  Exemption  
IRB Institutional  Review  Board  
MAS  Modified  Ashworth  Scale  
MS Multiple  sclerosis  
MSQLI  MS Quality  of Life Inventory  
NSTEP -MS NeuroStimulation  Therapy  to Alleviate  Symptoms  of 
Progressive  MS 
PHI Protected  Health  Information  
PI Principal  Investigator  
SAE  Serious  Adverse  Event/Serious  Adverse  Experience  
SCI Spinal  Cord  Injury  
SOP Standard  Operating  Procedure  
TUG  Timed  up and Go 
UADE  Unanticipated  Adverse  Device  Effect  
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 5 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   Study  Summary 
Title  A Pilot Study to Explore the Use of Percutaneous Spinal  
Stimulation  in Participants  with  Multiple  Sclerosis  
Running Title  ES in MS  
IRB Protocol 
Number 23-003967 
Phase Pilot  Study  
Methodology Prospective study  
Overall Study 
Duration 3-year duration 
Subject  
Participation  
Duration  
Less  than  2 months  per subject  
 
 
Objectives  a) Evaluate the effectiveness of percutaneous ES and task -specific  
training in participants with Progressive MS to impact motor 
function and spasticity. 
b) Investigate the potential of ES and task-specific training to  
impact non-motor spinal related dysfunction in the same  
participants.  
Number of Subjects  10 subjects  
Diagnosis and Main  
Inclusion Criteria  Multiple  Sclerosis  with  EDSS  of 6.5 
 
Study Device  Abbott percutaneous trial lead for epidural neurostimulation  
(Model  3086) 
 
Ripple  Nomad Neurostimulator 
 
Abbott clinician programmer, (Model 3874) 
Duration of 
Exposure All subjects will complete 1 month of temporary epidural spinal  
stimulation  (ES) with  task -specific training. 
Reference  therapy  The reference therapy  is clinical rehabilitation  with  MS.  
Statistical Methodology Descriptive  statistics  will be used  to describe  stimulation -related  
outcomes. Repeated measures analyses of variance will be used 
to detect  changes  in outcomes  pre- to post-ES and training.  
1 Introduction  
This document is  a protocol for a human research  study. This  study will  be carried  out in  
accordance with the procedures described in this protocol, applicable United States government regulations and Mayo Clinic  policies and procedures.  
 
Up to 75% of patients with MS develop progressive MS, and there is no current treatment to halt clinical progression or axonal loss in patients with progressive MS. Progressive MS is 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 6 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   defined by a sustained clinical worsening, typically of walking difficulties, over more than 1 
year in the absence of clinically detectable MS relapses or attacks (Thompson et al., 2018). Pathologically, it is characterized  by axonal loss in  the absence  of inflammatory  disease.  
Patients typically have progressive difficulty walking with associated leg spasticity and urinary, bowel and sexual dysfunction. 
 
Like MS, there is no cure for traumatic injury of the spinal cord which results in lifelong impairment of autonomic, sensory, and motor functions in regions of the body that are distal to the damaged areas of the spinal cord. In response to the complete lack of available therapies to restore volitionally -controlled lower extremity motor function, we recently 
conducted a pilot- phase clinical trial of epidural spinal electrical stimulation (ES) in  
combination with task -specific training; ES consists of an imp lanted stimulator and electrode 
array placed over the dura mater on the dorsal aspect of the spinal cord. ES with task -specific 
training resulted in unprecedented outcomes, such as restoration of standing and walking in humans previously diagnosed with complete paralysis of their lower extremities due to a traumatic  spinal cord  injury (SCI)  that occurred  several  years  prior (M. Gill et  al., 2020; M.  
L. Gill et al., 2018; Grahn et al., 2017). Likewise, other research teams have shown remarkable improvements  in spinal stimulation -enabled  motor functions that are retained  
after study participation in individuals with incomplete paralysis (Wagner et al., 2018). Herein, we propose leveraging the knowledge and expertise gained during our previous, and active, clinical trials of ES in participants with paralysis to determine the translational potential of epidural spinal electrical stimulation (ES) for improvement of motor function and  
spasticity in patients with myelopathy due to progressive multiple sclerosis (MS). The following are key  aspects  of the proposed work: 
 
• The proposed research is a pilot study which will explore epidural spinal stimulation  
(ES) in combination with task -specific training to improve lower limb function in 10  
participants  with Progressive  MS. 
• We will temporarily implant percutaneous ES leads through the skin overlying the  
lumbosacral enlargement  and remove the  leads following  the 4-week  study.  
• Participants will serve as their own control via a comparison of pre- and post- 
stimulation  outcomes  and outcome metrics  captured  during  ES and when  ES is off. 
• Safety will be continuously  evaluated  during  the 4-week  stimulation  and task specific 
training  period, and during  a post lead  removal neurologist visit.  
• The percutaneous leads are currently used clinically and are approved for patients  
with low back  pain;  use in participants  with MS will be possible  under  an FDA  IDE.  
 
1.1 Background 
Clinical Presentation  of Progressive Multiple  Sclerosis  
Multiple sclerosis (MS) is characterized by inflammatory central nervous system demyelination which can be subclinical or clinical. Clinical attacks typically manifest as  
optic neuropathy, sensory or motor myelopathy, which worsen over days to weeks and 
resolve over weeks to months. Most patients recover a significant degree of function following a clinical attack. Although clinical recovery occurs, persistent demyelination or partial remyelination of the lesion is present. The partially denuded axons redistribute sodium-potassium ATPase channels along the axon to compensate for the myelin loss. This results in increased energy expenditure, and loss of signal coherence in the remaining axons. 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 7 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   Mitochondrial expansion is necessary within the affected axons to compensate for the 
increased energy demand. Rapid mitochondrial expansion is associated with defects in mitochondrial replication, which ultimately leads to energy failure in the affected axons, and axonal loss. The stressed neurons subsequently retract synaptic connections and disengage from neural networks, triggering additional metabolic stress and engagement of transcriptional programs that push the neurons, axons, and circuits away from homeostasis. Clinically, this manifests as slow worsening of walking ability in the absence of clinical relapses. The presence of progressive disease does not exclude the presence of inflammatory disease.  Medications which have been approved for the treatment of progressive MS, 
exclusively treat the inflammatory component of the disease. No pharmacologic agent has yet been shown to prevent or reverse neuronal death and axonal loss in MS. This process occurs typically over decades, and appears to be an age dependent phenomenon, with the onset of motor progression becoming apparent in the late  fifth decade.  
 
Patients typically have gradual worsening of walking with associated leg spasticity and 
urinary, bowel and sexual dysfunction. Recent work from our group has shown that 
progressive motor dysfunction in MS is most common in patients who have spinal cord lesions or lesions in the brainstem involving the motor tracts (Kassa et al., 2021; Keegan et al., 2018; Sechi et al., 2019). This can occur even in the presence of a single cord lesion, and in the absence of brain disease. This provides a good rationale for targeting spinal cord disease as a therapeutic target in patients with progressive MS. Crucially, although progressive MS is characterized by axonal loss, complete loss of axons in any particular tract is unusual, meaning that if conduction block and slowing can be overcome, there is potential to facilitate  volitional motor  function. 
 
Stimulation  in MS and SCI 
Other research groups have shown benefit of transcutaneous (through the skin) lumbar stimulation in improving spasticity (Keegan et al., 2018), gait dysfunction (Keegan et al., 2018), postural instability (Roberts et al., 2021), and bladder dysfunction (Kreydin et al., 2020) in participants with MS. However continuous use of transcutaneous stimulation is impractical due to the delivery through the skin using an external device, and the results are likely to be short lived in the absence of continued stimulation. By contrast, permanently implanted  epidural stimulation  leads  are widely  used in clinical  practice for the management  
of chronic pain. These allow for continuous stimulation which can easily be manipulated to  
optimize response through means of a remote-control device. Significant progress has been made in the research use of these permanent leads for spinal stimulation in participants with SCI, to enable motor functions previously thought to be permanently lost after SCI. Specifically,  Harkema and  colleagues  reported  that,  after  months of rehabilitation  with  
permanently implanted spinal stimulators for ES, volitional control of joint- specific muscles  
and independent standing were achieved by four humans with motor complete paraplegia (Angeli et al., 2014; S. Harkema et al., 2011). Recently, our team reported that the same intervention enabled control of stepping leg movements, which over the course of rehabilitation,  translated to  independent standing and stepping (M. L. Gill et al., 2018; Grahn  
et al., 2017). 
 
Our initial case report described that our study goals were achieved within the first few sessions of permanent ES. To summarize, in the first study participant we enrolled, ES 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 8 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   enabled:  1) intentional control of motor activity  and leg movement; 2) standing; 3) 
intentional control of step-like movements while side lying with legs suspended in a gravity 
neutral  position, and  4) intentional control of bilateral  leg flexion and extension  while  upright 
with body weight supported by a harness. More recently, we reported that the same participant achieved independent standing, stepping on a treadmill while using arm support bars to maintain  balance,  and posture and over ground walking with  minimal  assistance (M. 
L. Gill et  al., 2018). To date,  the second participant demonstrated  similar  ES-enabled  motor 
achievements. In addition to reports of ES enabling lower extremity motor functions, improvements in upper extremity(Lu et al., 2016), cardiovascular (Aslan et al., 2018; S. J. Harkema, Legg Ditterline, et al., 2018; S. J. Harkema, Wang, et al., 2018; Herrity et al., 2018; West et al., 2018), and urologic functions (Herrity et al., 2018) have been reported in participants  with SCI.  
 
Prior to proposing a trial to assess the use of permanently implanted epidural spinal 
stimulation in participants with progressive MS, it is pertinent to assess whether these  
individuals are responsive to stimulation using a temporary percutaneous lead used 
commonly in clinical practice for low back pain and in research for participants with spinal cord injury.  
 
1.2 Investigational Device  
Abbott percutaneous trial lead for epidural 
neurostimulation  (Model 3086) 
 
Ripple Nomad  Neurostimulator 
 
Abbott clinician programmer (Model 3874) 
 
The temporary percutaneous implantation 
of epidural stimulation  (ES) electrode leads  
along the dorsal epidural surface of the lumbosacral enlargement (Figure 1) will be performed  to activate  spinal networks in 
ten humans diagnosed with Progressive MS. The externalized ends of the ES electrode leads will be connected to the Nomad neurostimulation system. By delivering ES over the spinal cord during task-specific  training  for one  month, we  
aim to quantify motor and non-motor improvements. 
 
1.3 Preclinical  Data  
Several decades of human investigation have focused on using ES to activate what was  
thought to be isolated spinal circuitry below the level of functionally complete SCI in order to study central pattern generator activity (Dimitrijevic et al. 1998; Jilge et al. 2004; Minassian et al. 2004; Roy et al. 2012) In 2011, Harkema and colleagues published a landmark report that after months of training, ES facilitated intentional control of joint- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Epidural stimulation (ES) will be  
delivered via percutaneous electrodes implanted  
over the dura mater of the lumbosacral  
enlargement.  
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 9 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   specific muscles and independent standing by a human with motor complete paraplegia 
(Harkema et al. 2011). The same research group successfully replicated their results in three additional subjects (Rejc et al. 2015; Rejc et al. 2017; Angeli et al. 2014). Based on these results, we initiated a clinical trial ([STUDY_ID_REMOVED]) and in 2017, we reported successful replication of Harkema et al., along with additional outcomes (Grahn et al. 2017). Based on observations made during [STUDY_ID_REMOVED], we have designed this protocol to gain additional scientific knowledge with respect to how ES may enable functions in humans with multiple sclerosis.  
 
1.4 Study  Rationale and Risk  Analysis (Risks  to Benefits  Ratio) 
 
1.4.1 Study  Rationale 
There is no cure for MS, which results in gradual loss of many functions and a significant reduction in quality of life. In parallel, there is no cure for traumatic injury of the spinal cord which  results  in lifelong  impairment of autonomic, sensory, and motor functions in regions 
of the body that are distal to  the damaged areas  of the spinal cord. In response to the 
complete lack of available therapies to restore volitionally -controlled lower extremity motor  
function, we recently conducted a pilot- phase clinical trial of epidural spinal electrical  
stimulation (ES) in combination with task -specific training for individuals with complete  
SCI. Likewise, other research teams have shown remarkable improvements in spinal stimulation -enabled motor functions that are retained after study participation in individuals 
with incomplete paralysis (Wagner et al., 2018). Herein, we propose leveraging the knowledge and expertise ga ined during our previous, and active, clinical trials of ES in 
participants with paralysis to determine the translational potential of ES for improvement of  
motor function and  spasticity  in patients with  myelopathy due to progressive MS.  
Completion  of the proposed experiments  in this protocol will provide data that  can be used to 
improve the scientific understanding of how ES  may enable  functional improvement after  
MS onset. This knowledge will be used to help determine if ES is a viable and useful tool in determining  which  subjects  may  be best suited  for permanently implanted ES  in the future.  
 
1.4.2 Anticipated  Risks  
Risks  associated with  task-specific training: 
In combination with ES, the rehabilitation techniques used during this study will focus on maximizing independence, load bearing, body position, and kinematics during motor tasks while providing the minimum amount of trainer assistance and body weight support necessary to safely perform tasks. Risks associated with daily training include skin irritation  
and minor bruising from  pressure  applied  during trainer assistance and body weight support, 
musculoskeletal  discomfort, fatigue,  and bladder or  bowel incontinence due to exertion  and 
abdominal pressure from support harness. There is a slight risk of fracture in the lower 
extremities. Orthostatic hypotension is a risk associated with abrupt position changes against 
gravity, specifically transitioning from sit to stand  quickly. 
 
Risks  associated with  weight -bearing  tasks:  
Risks include muscle  soreness,  fatigue,  skin irritation,  fracture,  changes  in blood pressure,  
and potential for a fall.  
 
 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 10 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   Risks  associated with  temporary  percutaneous  implantation of ES electrode leads:  
ES electrodes will be implanted via commonly used percutaneous implantation techniques 
for FDA -approved treatment of medically refractory pain conditions. Therefore, the risks 
associated with percutaneous implantation of the ES system for this study match the risks associated  with  ES system  implantation for  treatment  of FDA -approved conditions. 
• Undesirable changes in stimulation may occur over time. These changes in stimulation  are possibly related  to cellular  changes  in tissue  around the electrodes,  
changes  in the electrode position, loose electrical connections  and/or lead failure.  
• Placement  of a lead in the epidural space is a surgical  procedure that may  expose the 
patient to risks of epidural hemorrhage, hematoma, infection, spinal cord 
compression, and/or paralysis. 
• Radicular  chest  wall  stimulation.  
• Cerebrospinal fluid  (CSF)  leakage.  
• Persistent  pain at the electrode site or receiver  site. 
• Seroma at the incision  site.  
• Implant migration.  
• Allergic  or rejection  response to implant materials.  
• Lead  migration  and/or local  skin erosion. 
• Paralysis,  weakness,  clumsiness,  numbness, or pain below the level of  implantation.  
 
Risks  associated with  ES following  implantation: 
Hardware malfunction,  discomfort or abdominal tightness during ES,  increased  or decreased  
spasticity, bowel or bladder incontinence, shortness of breath, muscle soreness, or fatigue 
may occur  during ES. Autonomic dysreflexia is a possible risk factor  for subjects  as well.  
 
Risks  associated with  MRI  
Dislodgement of some metal implants and claustrophobia may occur during MRI. Subjects will be rigorously screened  in the same fashion as  clinical  patient  by MRI  technicians  prior to 
each scan. Earplugs will also be provided to keep MRI noise within a safe audible range. Due to the potential for tissue heating, image artifacts, induced voltages in the neurostimulator or leads, and lead dislodgement, MRIs will not be obtained after epidural stimulator implantation.  
 
Ri
sks associated with  electromyography  
Risks involved with EMG  include skin irritation  or allergic  reaction  from  the adhesive used to 
apply sensors.  
 Steps  taken  to minimize  the occurrence and severity  of associated risks:  
Trained study staff and medical technicians will directly oversee all tasks. Body weight support, a safety gait belt,  and other safety measures as necessary  will be  utilized  to lessen  
the risks involved with rehabilitation and weight-bearing tasks. To mitigate risks in general, the protocol will be conducted as stated, medical professionals will be consulted, and care will be provided to address  any study- related  concerns  that arise.  All members  of the 
research team will be trained to identify the occurrence of risks related to this study. If risk occurrence is  observed, study- related  activities will be halted  until appropriate medical  care 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 11 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   is given and it is deemed safe for the subject to continue study- related activities. Because the 
interventions have been used for individuals with subjects with spinal cord injury and 
subjects  will have been  carefully  screened,  we do not  anticipate  any serious adverse events  in 
this study. However, if they do occur, serious adverse events will be reported to the PI, medical monitor, IRB and FDA within the appropriate reporting timeframes. Adverse events will be reported to the PI, the site medical monitors IRB, and FDA within the appropriate reporting timeframes.  
 
1.4.3 Potential  Benefits  
The benefits which may result from this research study may include recovery of  
sensorimotor function, recovery of bladder, bowel, or sexual function, improved thermoregulation, improved body mass  composition, and  improved sense  of wellbeing. The  
certainty  and degree to  which these benefits may  or may not occur is unknown. 
 
1.5 Anticipated  Duration of the Clinical Investigation 
The anticipated duration of study participation for each human subject is approximately 2 months. Subjects  will receive ES and task-specific training  sessions for 1 month. Electrodes  
will be removed following 1 month of sessions.  
 
2 Study  Objectives 
We propose to compare motor and non-motor outcomes over the course of 1 month of ES in combination with task -specific training in  participants with  Progressive MS.  
 
2.1 Primary  Objective  
The primary  objective is to evaluate the effectiveness  of percutaneous ES  and task -specific 
training over 1 month in participants with Progressive MS to impact motor function and spasticity.  
 
2.2 Secondary  Objective  
The secondary objective is to investigate the potential of ES and task- specific training to  
impact  non-motor spinal related  dysfunction in the same participants  with Progressive MS. 
3 Study  Design  
3.1 General  Design  
This is a pilot study that will include a total of 10 subjects with Progressive MS (EDSS 6.5). All subjects will complete 1 month of ES and task -specific training. Expected duration of 
subject  participation is less than  2 months. Baseline assessments will be obtained prior to 
implantation and post- stimulation assessments will be obtained prior to explantation, with 
stimulation on and off. 
   
 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 12 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   SCREENING  BASELINE  STIMULATION  POST - 
STIMULATION  
STUDY  END   
 
 
Assessment of  
Inclusion/Exclusi  on 
criteria by  study 
team  Baseline  
Assessments  Minimum  12 Sessions  End Assessments  
Clinical,  
Electromyography,  
Movement  
Assessments  & 
Surveys  Stimulation + Task - 
Specific  Training  Clinical,  
Electromyography,  
Movement  Assessments 
& Surveys  
No Stim  Percutaneous  
Stimulation  Stim  on/Stim  off 
1-month pre - 
enrollment   
Week 0-1  
Weeks  1-4  
Week 4-5 
 
 
3.2 Primary  Study  Endpoints  
 
Due to the pilot phase design of this clinical trial, it is not feasible to designate primary study  
endpoints. With this in mind, we do consider the voluntary movement assessments, gait 
analysis, and functional mobility tests to be the primary sets of endpoints used to quantify ES-related  datasets  associated with  addressing the specific aims  of this proposal. 
 
Secondary  Study  Endpoints  
Secondary  endpoints include spasticity  and MS Quality  of Life Inventory.  
 
 
 
3.3 Primary  Safety  Endpoints  
Primary safety endpoints of the study will be oriented to adverse events that could originate  
from  the implantation  of the ES  electrodes,  or the operation of the neurostimulator device as  
well as to  those that  could arise from performing  the task -specific  training  sessions.  
Participants will be asked to report any discomfort that they encounter throughout the study. A detailed selection of the candidates by the Principal Investigators and the study team will be crucial to select individuals who fit the inclusion criteria of the study, minimizing risk for  Pre/ 
No 
StimPost/ 
Stim 
ON 
and 
OFF
Outcomes Specific Measure wk 0 wk 1 wk 2 wk 3 wk 4 wk 4/5
Gait Analysis EMG, Kinematics, Kinetics X X
Voluntary Movement EMG, Kinematics X X X X
Spasticity MAS, Pendulum Test X X
Functinal Mobility TUG X X
MS Quality of Life Inventory MSQLI X XStimulation + Task-specific 
Training
Primary
Secondary
  ES in MS Version 2.2
Revised 06/23/2023
Page 13of 33
Kristin D. Zhao, Ph.D.                                                                                                                                                      CONFIDENTIALpotential adverse events throughout the study. Subjects will undergo a screening phase
oriented to identify conditions that could potentially represent a higher than the expected riskforconducting this study.
To visualize electrode positioning of the ES device, X-ray imaging will be performed. Tolimit adverse events that could result from operating the device, stimulation parameters willbeselected within safe ranges as provided by the manufacturer.
4Subject Selection, Enrollment andWithdrawal
Ten subjects with a diagnosis of Progressive MS (EDSS 6.5) will be enrolled. Subjects willbeselected based on the following criteria:
4.1 Inclusion Criteria
•Myelopathy secondary toProgressive MS
•Noclinical orradiologic MS relapses for > 5 years
•EDSS score of6.5(constant bilateral assistance required towalk about 20meters
without resting) as assessed by a Neurologist with a specialty in MS
•Able to ambulate 10 feet independently with or without gait aid use
•Atleast 21years ofage
•Nochanges tospasticity medications ordalfampridine over thelast 3 months
4.2 Exclusion Criteria
•Currently aprison inmate, orawaiting trial, related tocriminal activity
•Pregnancy at thetime of enrollment
•History ofchronic and/or treatment resistant urinary tract infection
•Spasticity (grade of 4) measured bilaterally in two muscle groups using Modified
Ashworth Scale (MAS). Muscle groups tested will include bilateral knee flexors, 
extensors; ankle plantarflexors, dorsiflexors
•Unhealed decubitus ulcer
•Unhealed skeletal fracture
•Receiving diathermy treatment
•Active participation inaninterventional clinical trial
Subject 1
Screening and baseline visit
Stim +task-specific training,
post-visit
Subject 6
Subject 7
Subject 8
Subject 9
Data Analysis, Interpretation, Documentation
Subject 10
Subject 5
Subject 4
Subject 2
Subject 3
34-36
 31-33
 28-30
 25-27
 22-24
 19-21
 16-18
 13-15
 10-12
 7-9
 4-6
 1-3
Month
Year 3
 Year 2
 Year 1Study Start -up,
Regulatory Approvals, 
Recruitment, Staff
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 14 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   • Any illness or condition which, based on the research team’s assessment, will  
compromise the patient’s ability to comply with the protocol, patient safety, or the 
validity  of the data collected during this study. 
• History of coagulopathy or other significant cardiac or medical risk factors for 
surgery  
• Ventilator -dependent respiration  
• Diagnosed with cardiopulmonary dysfunction (e.g., chronic obstructive pulmonary  
disease,  cardiac failure, or  heart  arrhythmia) 
• Untreated clinical  diagnosis of depression 
• History of frequent hypotension characterized by light headedness, or loss of 
consciousness 
• History  of frequent hypertension characterized  by headache, or bradycardia 
• Any active, implanted medical device  
• Treatment of chemodenervation and/or neurolysis during the trial, or within 6 
months of initiating the trial  
 
4.3 Subject  Recruitment,  Enrollment  and Screening  
We will initially recruit participants from existing resources including individuals who have 
expressed interest in clinical research through the Mayo Clinic Multiple Sclerosis Clinic,  
Mayo Clinic volunteer research participant database, Mayo Clinic clinical trials website,  
Mayo Clinic electronic medical record, and ClinicalTrials.gov. The Mayo Clinic Center for 
Multiple Sclerosis and Autoimmune Neurology (CMSAN) has prospectively enrolled over 1000 patients  with  MS in an observational biorepository study. These patients  are consented  
for further contact to discuss enrolment in clinical trials, such as the proposed study. In addition, a subspeciality MS clinic is run daily, 52 weeks per year. Patients are seen by  
neurology, physiatry, urology, ophthalmology, and neuropsychology. Mayo Clinic’s prior research in progressive MS, particularly in remyelinating therapies has resulted in a continuous stream of solicitations from candidates interested in therapy for progressive MS. The rate of up to four subjects enrolled annually will be easily achievable. We have successfully recruited individuals with similar inclusion/exclusion criteria as the proposed work, and we have had very  successful recruitment, retention, and compliance.  
 
Prior to participating in the screening phase, a member of the research team will provide an 
explanation of the study and  answer  questions asked by the potential study participant.  
Participants will be given sufficient time to make an informed decision, review relevant 
informed consent documents, and ask questions. Once questions and concerns have been addressed to the potential subject’s satisfaction, the informed consent form will be signed and dated by the participant and the PI. A copy of the signed consent documents will be provided to the subject. Following informed consent, screening tests will be performed. A final decision  on study participation will be made by the PI  and study team. 
 
4.4 Early  Withdrawal of Subjects  
Subjects will be informed that they have the right to withdraw from the study at any time. Similarly,  the PI has the authority to withdraw the subject from the study at any  time.  
 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 15 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   4.4.1 When  and How to Withdraw Subjects  
Factors  that may lead to withdrawal:  
• Study subject  health  concerns 
• Protocol violation  (e.g., non- compliance)  
• Study- related  serious adverse events  
• Study subject’s decision to pursue activities outside of the study protocol, that in the 
opinion of the PI, may  compromise  data collected  within the  study protocol 
• The emergence of other problems, events,  or information, that  may  adversely  affect  
the rights, safety, or welfare of the study subject, or may substantially compromise data collected within the  study protocol 
If a serious adverse event occurs during an activity described in this protocol, a consensual decision will be made between the study subject and the PI regarding withdrawal from the  
study. 
In the event of study withdrawal, the ES electrodes will be explanted. If explanation surgery 
is urgent due to concern for the subject’s health, the cost of the explanation procedure will be covered by the research study. Aside from standard recovery, no adverse effects are anticipated  from the  removal  of percutaneous electrical  stimulator.  
If a subject fails to attend protocol activities and fails to respond for follow-up, a communication  attempt will be made to determine  if non- compliance is related  to an adverse  
event.  
 
4.4.2 Data  Collection  and Follow- up for Withdrawn Subjects  
If a subject withdraws or is withdrawn from the study for any reason before study completion, an attempt will be made to carry out an exit interview. The reason for withdrawal  will be  documented by the research team.  
 
5 Study  Device  
5.1 Description  
Epidural  spinal  cord  stimulator  
(Model  3086, Abbott  Neuromodulation; Nomad,  Ripple  Neuro)  
The ES electrode lead is an implantable neurostimulation device that is FDA -approved for 
treatment of neuropathic pain disorders. Up to two ES electrode leads will be implanted temporarily along the dorsal epidural surface of the lumbosacral enlargement (i.e., L2- S1 
spinal segments). The externalized ends of the ES electrode leads will be connected to the Nomad  neurostimulation  system  to deliver  electrical  pulse waveforms  to the epidural surface.  
 
5.2 Method  for Assigning  Subjects  to Treatment  Groups  
Subjects  will be all receive ES combined with  task-specific training. 
 
5.3 Preparation  and Administration/Implantation  of Investigational Device  
Description  of ES system  implantation/administration  
We recently published a detailed explanation of the procedure to implant a permanent 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 16 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   electrode array connected to an implanted pulse generator, along with a detailed description 
of the electrophysiological approach  used  to guide electrode positioning over  the lumbosacral 
enlargement in humans with SCI (Calvert, 2018). The same approach will be used during this study to guide electrode placement via electrophysiological monitoring of spinal motor evoked potentials.  
 
The procedures for percutaneously implanting Abbott ES electrodes are performed daily at 
Mayo  Clinic  to treat patients  suffering  from  neuropathic pain. Prior to implantation,  subjects  
will undergo a pre-operative evaluation  to minimize  the risk  of unexpected complications.  
Pre-operative assessments may be performed  to check  for any  signs of infection. 
 
To implant the temporary spinal electrodes, under fluoroscopy an electrode insertion 
needle will be  placed into the epidural space using a paramedian approach and  loss of 
resistance technique to advance through the ligamentum flavum, followed by fluoroscopic visualization of the needle’s position. Once positioning is confirmed, the needle stylet will 
be removed, and  the needle will be advanced   into the epidural space.  
 
 
Then, the leads are advanced in an anterograde fashion to the level of the lumbosacral enlargement  utilizing  fluoroscopic guidance. Following electrophysiologic confirmation of 
electrode positioning, the needle and stylet will be removed, the implantation site will be  
dressed, and the leads will be secured to the skin via an adhesive bandage. The implantation site will be  monitored for signs of infection, tissue erosion, or dislodged lead wires.  One day 
post implantation, the first follow up will take place to evaluate for adverse events. Trained 

  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 17 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   team members will monitor the percutaneous site on an ongoing basis during training 
session to ensure the site remains intact and sterile. Study team members have received training from a registered nurse within the pain specialty program at Mayo Clinic. 
 
Procedure to explant ES 
 electrode leads  
After completing task -specific training with ES, the adhesive bandage covering the 
implantation site will be removed, the incision site will be opened, and the leads will be  
carefully  retracted.  Finally, the incision site  will be  cleaned and  dressed.  
 
If complications associated with temporary lead implantation (e.g., infection, severe lead migration, device malfunction, etc.) are observed, the PI will make an informed decision whether  to perform  explantation prior  to completion of  task-specific training. Participants 
will be followed up within 5 days of explantation for adverse events. They will be provided information for monitoring the site remotely as well.  
 
5.4 Subject  Compliance Monitoring  
Throughout the study, research staff will monitor study protocol compliance. This will include review and verification of all protocol- related procedures and records. The PI will  
oversee compliance and  determine  the appropriate response to non- compliance events.  
 
5.5 Prior and Concomitant Therapy  
A subject’s prior therapy regimen will not impact the PI’s decision regarding enrollment into 
the study. If the subject fits the inclusion criteria and does not demonstrate any exclusion criteria  characteristics,  prior exercise  or therapy  programs will not exclude their participation  
in the study. While enrolled in the study, subjects will be asked to follow the instructions from the study staff regarding concurrent activities. For example, if the study subject performed locomotor training at a local gym prior to the study, they would be asked to  
continue that activity while  participating in the trial.  
 
5.6 Packaging and Labeling  
The packaging of the devices  will be from  the manufacturer’s  clinical  supply. The  following 
will be added to the devices used within this investigation: “CAUTION – Investigational Device. Limited by Federal (or United States) law to  
investigational use” 
 
5.7 Masking/Blinding  of Study  
This is an unblinded study. The  PIs, co-investigators, and  subjects  will not be blinded, and  
all participants  will receive  the same treatment.  
 
5.8 Receiving,  Storage,  Distribution  and Return  
 
5.8.1 Receipt  of Investigational Devices  
The percutaneously-delivered ES electrode leads will be acquired either through purchase or donation from  Abbott. A representative from  Abbott will  ship the devices  to Mayo  Clinic  and 
will be properly inventoried prior to  the scheduled  date of surgical  implantation.  
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 18 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL    
The Nomad  neurostimulation  system  has been  purchased  from  Ripple Neuro, shipped to  
Mayo  Clinic, and inventoried within the ART  Lab. 
 
Any product discrepancies  or damage will be documented in the study files  and the supplier 
will be notified. Then, appropriate action  will be  taken by the PI  to fully  address the issue.  
 
5.8.2 Storage 
ES electrode leads will be stored within a secured surgical materials area at Mayo Clinic.  
Access  to this area is granted solely  to Mayo  Clinic  staff involved in  surgical implantation  
procedures. 
 
The Ripple Nomad  system will be stored in the ART  Lab,  which  is a secured  area  that can  
only be accessed by ART  Lab staff.  
 
5.8.3 Distribution  of Study  Device  
In accordance with Mayo Clinic policy, the brand, model, date of implantation, and date of 
explantation of all ES electrode leads will be recorded in the Surgical Inventory Management System. This information will be made available within the electronic medical record of each  
subject.  Additionally, a copy of this information  will be stored  within  each  subject’s  case file. 
 
5.8.4 Return  or Destruction  of Study  Device  
At routine intervals and at the completion of the study, there will be a reconciliation of 
devices shipped, devices utilized, and devices remaining. This reconciliation will be logged  
on the Device Accountability form, signed and dated. Any discrepancies noted will be documented, the PI will be notified, and an investigation will be conducted to determine the cause of the discrepancy.  
6 Study  Procedures  
6.1 Screening  
Subjects will complete a variety of assessments and procedures to determine their enrollment  
eligibility. When possible, eligible subjects will have their screening data used as baseline data collection. The following tests/activities will be performed to determine eligibility based  
on the inclusion/exclusion criteria  listed in this  document. 
• Review  of available medical  records  
• Neurology and Physical Medicine and Rehabilitation  clinical  exams  
• EDSS  score evaluation  
• Pregnancy  test 
• Spasticity  examination  
• Evaluation of rehabilitation  task ability  and range of motion  of impaired  joints  
• S
pine MRI  
• Body weight 
 
 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 19 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   6.2 Epidural  Electrical  Stimulation  (ES)  
Study engineers, physical therapists, and research technicians perform the device 
p
rogramming and determine maximum stimulation parameters in real time. Device operators 
have been trained by industry partners ( i.e., Abbott) on device manipulation during previous 
studies utilizing the same technology in SCI patients.  
 
T
he surface area of each OCTRODE electrode is 0.1319 cm^2 based on manufacturer’s 
specifications.  
Based on literature, we conclude that stimulation that results in a charge density per pulse of 
no more than 30 µC/cm^2, poses no safety concerns. 
The charge density per pulse is defined by multiplying the stimulation current amplitude 
originating from an electrode by the pulse width of the stimulation pulse and dividing by the total electrode surface area.  
The lower limit for current amplitude per electrode that will be applied in this study is 0.1 mA; The lower limit for the pulse width that will be applied in this study is 250 µs . 
Therefore, if we applied the lower limit stimulation amplitude of 0.1 mA, the upper limit of pulse width that could be selected to stay below the current density per pulse threshold per pulse is 39570 µs; since the manufacturing limit of the device is 1000 µs, 1000 µs will be selected as the pulse width upper limit for this study.   Similarly, if a stimulation pulse width 
of the stated minimum of 250 µs was selected, up to 15.8 mA could be applied to stay below the charge density per pulse threshold; therefore, 15.8 mA will be selected as the upper limit for current density in this study. No combination of parameters will be selected to drive the charge density per pulse over 30 µC/cm^2 (S.F Cogan et al., 2016; Mccreery et al., 1990). 
 ES task -specific daily training will consist of lower extremity stretching, supine and side 
lying activities, seated trunk strengthening and balance activities, and locomotor training 
including task-specific stand and step training on a treadmill and over ground. Standing and stepping training activities may be performed with body weight support and trainer assistance as needed to  ensure the safety of  subjects.  
 
Training sessions will begin upon completion  of baseline testing.  Subjects  will participate  in 
3 days a week  training regimen  over 1 month with  a goal of achieving  at least  12 sessions.  
Activities include tasks specific to supine intentional leg movement training, balance  
training, stand and step (reciprocal flexion/extension) training. Heart rate will be recorded prior to, and after, each session, and at any time the intervention is paused due to a concern. Environments include the body weight support treadmill (BWST) system to allow trainer-assisted stand and step  activities as needed, custom standing frame, and a hi/lo mat for 
supine and seated activities.  As the subjects progress their intentional motor ability with 
standing and stepping, BWS will be removed, and assist will continue to be provided on an as 
needed basis. Any visit to the laboratory when ES is enabled will be considered a training session. Activities chosen for each  session will be  based on the subject’s progression. At or 
near the conclusion of the training regimen, a Neurologist with a specialty in MS will conduct a clinical examination with stimulation turned on.  
Over the course of rehabilitation sessions with ES, one additional x-ray may be performed to 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 20 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   visualize the location of implanted leads. This x- ray will be performed if stimulation -enabled 
motor activity is remarkably inconsistent from session to session, which might indicate 
migration of either  ES lea d. 
 
6.3 Period  of Follow- Up after ES 
After 1 month of ES and task-specific training, each subject will be asked to complete 
follow-up assessments.  
 
6.4 Outcome Measures  
The following outcome measures will be collected with tests occurring over an approximately one-week period of time for each time point. Photographic and video images will be recorded throughout the study but will not be shown to anyone outside the study team without the subject’s written consent. 
 
 
 
Aim 1 will quantify the effect of ES and task -specific training on lower extremity motor 
function in individuals with severe lower extremity motor disability due to progressive MS using the primary outcomes of kinematics (movement), kinetics (forces), and electromyography (muscle activity, EMG) collected during gait, standing, and side lying motor tasks. Data will be reduced and summarized using standard biomechanical approaches, to quantify gait rhythm, lower extremity joint and body center of mass ranges of motion (during gait, standing, and side lying), and timing of muscle activations and ground reaction force peaks. Secondary outcomes include functional mobility assessments utilizing motion capture data, as well as the Timed Up and Go (TUG) test. Safety  and tolerability will be 
assessed while monitoring vital signs and stimulation responsiveness during daily sessions and testing dates. 
 
Aim 2 will determine the impact of ES and task -specific training on non-motor spinal 
related dysfunction in individuals with severe lower extremity motor disability due to  
progressive MS using the primary outcomes of the qualitative pendulum test (Smith et al.,  
2000) and the Modified Ashworth Scale to describe spasticity levels. Secondary outcomes  
will include the MS Quality of Life inventory that includes questions about bowel, bladder and sexual function, quality of life  and pain, among others. 
 
Aim 3 will be an exploratory aim to collect electrophysiological and biomarker data that may help us gain a mechanistic understanding of findings in Aims 1 and 2. To assess the  Pre/ 
No 
StimPost/ 
Stim 
ON 
and 
OFF
Outcomes Specific Measure wk 0 wk 1 wk 2 wk 3 wk 4 wk 4/5
Gait Analysis EMG, Kinematics, Kinetics X X
Voluntary Movement EMG, Kinematics X X X X
Spasticity MAS, Pendulum Test X X
Functinal Mobility TUG X X
MS Quality of Life Inventory MSQLI X XStimulation + Task-specific 
Training
Primary
Secondary
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 21 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   functional states of spinal connectivity , we will deliver transcutaneous electrical stimulation  
via pulses of 1 ms duration at intensities of up to 100 mA using biphasic, charge balanced 
stimulation (DS8R, Digitimer Ltd., UK). Stimulation  will be delivered to the skin over the 
intra-spinous space between the spinous processes of the T10, T11, T12, L1, L2vertebrae,  
with subjects in  a supine position. Evoked 
potentials will be recorded via surface EMG electrodes placed bilaterally over the rectus  
femoris,  vastus lateralis,  medial  hamstring, tibialis  anterior,  medial  gastrocnemius,  and soleus 
muscles. We will record evoked potentials while relaxed using stimulus intensities from 1 - 
100 mA at increments of 10 mA for each stimulus locationT10 -L2. Stimulus intensities that 
are at the threshold for evoking motor potentials will be delivered during the following actions: while attempting prolonged maximal contractions of all muscles; during attempts to  
contract  the left leg; and  during attempts to contract the right leg. 
 
Gait analysis: Full body kinematic parameters will be acquired with a computerized video motion analysis system. A surface electromyography (EMG) system will be used for data collection.  Muscle activity will be collected from all or a subset of the following lower  
extremity and trunk muscles: soleus, gastrocnemius, tibialis anterior, hamstrings, quadriceps, hip adductors, gluteus maximus, gluteus medius, abdominals and spinal extensors. Ground reaction force data will be acquired from force plates or pressure mat  
technology located in the floor or as in-shoe sensors. EMG and ground reaction force data will be time-synchronized with the motion cameras.  
 
Voluntary movement in side -lying and supine postures: Voluntary movement data will be 
acquired during a variety of volitional tasks including standing, and supine and side-lying stepping movements. Kinematics and EMG measurements will be obtained from a motion  
analysis system and surface EMG system.  All or a subset of the following muscles or 
muscle groups will be tested: soleus, gastrocnemius, tibialis anterior, hamstrings,  
quadriceps, hip adductors, gluteus maximus, gluteus medius, abdominals and spinal extensors. 
 
Spasticity: One or both of the following will be used to measure lower extremity spasticity: the Modified Ashworth Scale (MAS) (Bohannon et al., 1987) where the subject will be 
placed in a supine position and flexor and extensor muscles are assessed according to the MAS protocol; and the pendulum test  which is a biomechanical method of evaluating 
muscle tone using surface- based kinematic assessments that uses gravity to provoke muscle 
stretch reflexes during passive swinging of the lower  limb.  
 
Functional mobility test: The following test will be performed: Timed Up and Go (TUG) (
Podsiadlo et al., 1991) . The TUG test is  used to assess a person's mobility and requires 
both static and dynamic balance. 
 
MS QOL  Inventory (MSQLI): Multiple  Sclerosis  Quality  of Life Inventory (Fischer  et al., 
1999), a comprehensive outcomes assessment battery will be administered to assess many facets of the participants’ quality of life. Several scores, are captured, including Overall Health Status, Modified Fatigue Scale, Sexual Satisfaction Scale, Bladder Control Scale,  
Bowel  Control Scale,  Perceived  Deficits  Questionnaire and Mental  Health  Inventory. 
 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 22 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL    
7 Statistical Plan  
7.1 Sample  Size Determination  
Due to the pilot phase of this study, no formal power calculations were performed for this 
proposal. The number of subjects was selected based on budgetary, space, and personnel time constraints. Ten participants (five males; five female) will be enrolled to complete this study,  
depending on need for contingency subjects. Participants will receive 4 weeks of ES and serve as their  own control. 
 
7.2 Statistical  Methods  
Statistical Methods: Continuous data will be summarized as median (inner quartile range). Categorical data will be presented as frequency (percentage). Graphical presentations of 
subject -level data will be used for all endpoints. Individual data points will be plotted over 
time,  from pre  to post stimulation and training. 
 
Modeling: Statistical models will be used both to estimate the ES effect on endpoints, as well as to provide estimates  of variability to  enable sample  size estimation for  future  studies. 
Models for post- ES treatment  will be fit using linear  regression  using the baseline measure as 
a covariate. Both the ES treatment effect and the residual variance estimate will be reported.  
Standard deviations of the differences in pre- and post -ES measurements will also be  
reported. Furthermore, correlations between pre- and post- ES assessments, as well as post  
task specific training stim-off and stim-on assessments will be calculated to aid future study design. Transformations of endpoints to achieve symmetry in the distribution (normality will be difficult to assess  with  this sample  size)  will be used as necessary.  
 
Handling of Missing Data: Due to the small sample size, sophisticated missing data  
techniques like imputation are likely to be unreliable. For all analyses, only subjects with complete data for the necessary analysis will be included. We will attempt to limit missing  
data by only enrolling participants who have the physical capacity to complete the training sessions. Only prospective enrollees who have been fully optimized from a rehabilitation point of view will be offered enrollment in the study. To minimize the financial burden on study participants and their families, they will be offered money to offset the cost of travel and accommodation during the study. If a study participant ends the study early, a similar replacement participant will be sought. Missing data in survey instruments will be minimized  
by allocating time during the study for survey completion, and inspection for completion by study coordinators before moving to the next component of the study. 
 
7.3 Subject  Population(s) for Analysis 
All-completed  population: Only  subjects  who completed  all study related procedures  and 
follow-up will be included; however, the PI may adjust this to include a subject who completed  most of the study visits and procedures. 
 
  
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 23 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   8 Safety and Adverse  Events  
All adverse events  occurring during the study, including those not meeting  the criteria  of an 
Unanticipated  Adverse Device Effect  (UADE)  will be recorded  on the appropriate case 
report  form.  Records  of these events  will be maintained  and reports  submitted  to the FDA  
and IRB according to the regulatory requirements. Expected clinical adverse events and  
nonsignificant (not serious) clinical  adverse events will not be reported. 
 
8.1 Definitions  
Unanticipated Adverse Device Effect  (UADE)  
A UADE is any serious adverse effect on health or safety or any life-threatening problem or 
death caused by, or associated with, a device if that effect, problem or death was not previously identified  in nature,  severity,  or degree of  incidence in the investigational plan  or IDE application 
(including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of  subjects. 
 Adverse Effect  (Event)  
Any untoward medical  occurrence in a subject  involved in clinical  study of an investigational 
device; regardless of the causal relationship of the problem with the device or, if applicable, other study related treatment(s).  
 Associated with the investigational device:  There is a reasonable possibility that the adverse 
effect may  have been caused  by the investigational device. 
 Life-threatening  adverse effect:  Any adverse effect  that places  the subject,  in the view  of either 
the investigator or the sponsor, at immediate risk of death from the effect as it  occurred . It does 
not include a reaction that, had it occurred in a more severe form, might have caused death.  
 Serious adverse effect:  An adverse effect is considered “serious” if, in the view of either the 
investigator or the sponsor, it results in any of the following outcomes: death  
• a life-threatening AE 
• inpatient hospitalization  or prolongation of existing  hospitalization  
• a persistent  or significant disability/incapacity  
• a congenital anomaly/birth defect.  
 U
nanticipated adverse effect:  Any adverse effect, the nature, specificity, severity, or frequency 
of which is not consistent with the risk information in the clinical study protocol or elsewhere in 
the current  IDE application. 
 General  Physical Examination Findings  
At screening, any clinically significant abnormality should be recorded as a preexisting condition. At the end of the study, any new clinically significant findings/abnormalities that meet 
the definition of an adverse event must also be recorded and documented as an adverse event.  
 Hospitalization,  Prolonged Hospitalization  or Surgery  
Any adverse event that results in hospitalization or prolonged hospitalization should be 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 24 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   documented and reported as an unanticipated adverse device effect unless specifically  instructed 
otherwise in this protocol. Any condition responsible for surgery should be documented as  an 
adverse  event  if the condition meets  the criteria  for an  adverse event.  
 
 
Neither the  condition,  hospitalization, prolonged hospitalization, nor surgery  are reported as  
an adverse event in the  following circumstances:  
• Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures for a preexisting condition. Surgery will not be reported as an outcome of an 
AE if the purpose of the surgery was elective or diagnostic and the outcome was uneventful
 
• Hospitalization or prolonged hospitalization for therapy of the target disease of the study, unless it is a worsening or increase in frequency of hospital admissions as judged by the clinical investigator
 
 Post-study  Adverse Event 
All unresolved adverse events should be followed by the investigator until the events are resolved, the subject is lost to follow-up, or the adverse event is otherwise explained. At the  last 
scheduled visit, the local investigator should instruct each subject to report, to the local investigator, any subsequent event(s) that the subject, or the subject’s personal physician, believes might reasonably be related to participation in this study. The local investigator should notify the study regulatory sponsor of any death or adverse event occurring at any time  after a 
subject  has discontinued or terminated  study participation  that may reasonably be related to this 
study. The sponsor should also be notified if the local investigator should become aware of the 
development of problems, cancer or of a congenital anomaly in a subsequently conceived  
offspring  of a subject  that has participated  in this  study. 
 Preexisting  Condition 
A preexisting condition is one that is present at the start of the study. A preexisting condition should be recorded as an adverse event if the frequency, intensity, or the character of the condition worsens during the study period.  Unanticipated Problems  Involving Risk  to Subjects  or Others  (UPIRTSO)  
Any unanticipated  problem or adverse event  that meets  all of the following three criteria:  
Serious: Serious problems or events that results in significant harm, (which may be physical, 
psychological, financial, social, economic, or legal) or increased risk for the subject  or others 
(including individuals who  are not research  subjects). These include:  
(1) death; (2) life threatening adverse experience; (3) hospitalization - inpatient, new, or 
prolonged; (4) disability/incapacity - persistent or significant; (5) birth  defect/anomaly; (6) 
breach of confidentiality and (7) other problems, events, or new information (i.e. publications, DSMB reports, interim findings, product labeling change) that in the opinion of the local investigator may adversely affect the rights, safety, or welfare of the subjects or others, or substantially compromise the research  data,  AND  
Unanticipated: (i.e. unexpected) problems or events are those that are not already  d
 escribed  as 
potential risks  in the protocol, consent document, not listed  in the Investigator’s Brochure, or not 
part of an underlying disease. A problem or event is "unanticipated" when it was unforeseeable at the time of its occurrence. A problem or event is "unanticipated" when it occurs at an 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 25 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   increased frequency or at an increased  severity  than expected, AND  
Related : A  problem or event is "related" if it is possibly related to the research  procedures.  
8.2 Recording  of Adverse Events  
At each contact  with  the subject,  the investigator must seek  information  on adverse events  by 
specific questioning and, as appropriate, by examination. Study subjects will be routinely 
questioned about adverse effects at study visits. Information on all adverse events should be recorded immediately in the source document, and also in the appropriate adverse event section of the case report  form  (CRF)  or in  a separate AE worksheet. All  clearly  related  
signs, symptoms, and abnormal diagnostic, laboratory or procedure results should be recorded  in the source document. 
 
All adverse events occurring during the study period must be recorded. All observed or volunteered adverse effects (serious or non-serious) and abnormal test findings, regardless of the treatment group if applicable or suspected causal relationship to the investigational device or if applicable  other study treatment  or diagnostic product(s) will be recorded  in the 
subjects’ case history.  For all adverse effects sufficient information will be pursued and or 
obtained as to permit; an adequate determination of the outcome, an assessment of the casual  
relationship between the adverse effect and the investigational device or, if applicable other  
study treatment or diagnostic product. The clinical course of each event should be followed until resolution, stabilization, or until it has been ultimately determined that the study  
treatment or participation is not the probable cause. Serious adverse events that are still  
ongoing at the end of the study period must be followed up, to determine the final outcome. Any serious adverse event that occurs after the study period and is considered to be at least possibly related to the study treatment or study participation should be recorded and reported immediately.  
 
Causality  and severity  assessment  
The sponsor-investigator will promptly review  documented adverse effects  and abnormal test 
findings to  determine  1) if the abnormal test  finding should be classified as  an adverse  effect;  
2) if there is a reasonable  possibility  that the adverse effect  was caused  by the investigational 
device or other study treatments; and 3) if the adverse effect meets the criteria for a serious  
adverse effect.  
 
If the sponsor-investigator’s final determination of causality is “unknown and of questionable relationship to the investigational device or other study treatments,” the adverse effect will be  
classified  as associated  with  the use of the investigational device or other  study treatments  for 
reporting purposes. If the sponsor-investigator’s final determination  of causality  is 
“unknown but not related to the investigational device or other study treatments,” this determination and the rationale for the determination will be documented in the respective subject’s  case history. 
 
8.3 Sponsor -Investigator Reporting of Unanticipated Adverse Device Effects and  
Unanticipated Problems  
When an adverse event has been identified, the study team will take appropriate action  
necessary to protect the study participant and then complete the Study Adverse Event 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 26 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   Worksheet and log. The sponsor -investigator will evaluate the event and determine the  
necessary  follow-up and reporting required. 
 
The sponsor-investigator will promptly review documented Unanticipated Adverse Device 
Effects and as necessary shall report the results of such evaluation to FDA within 10 working days and Mayo IRB within 5 working days of initial notice of the effect. Thereafter the  
sponsor-investigator will submit such  additional reports  concerning the effect  as requested.  
 
8.3.1 Sponsor -Investigator Reporting,  Notifying  Mayo IRB 
The sponsor-investigator will report to the Mayo IRB any UPIRTSOs and Non- UPIRTSOs  
according  to the Mayo  IRB Policy and Procedures. 
 
8.3.2 Sponsor -Investigator Reporting:  Notifying  the FDA  
The sponsor-investigator will report  to the FDA  all unanticipated  adverse device effects  
according  to the required reporting timelines, formats  and regulations. 
 The sponsor-investigator will submit a completed  FDA Form  3500A to t
he FDA’s  Center  for 
Devices and Radiological Health for any observed or reported adverse effect that is determined to be an unanticipated adverse device effect.  A copy of this completed form will 
be provided to the DSMB  and all participating sub-investigators. 
 T
he completed FDA Form 3500A will be submitted to the FDA as soon as possible and, in 
no event, later than 10 working days after the sponsor- investigator first receives notice of the  
adverse effect.  
 
If the results of the sponsor-investigator’s follow-up evaluation shows that an adverse effect 
that was initially  determined  to not constitute  an unanticipated  adverse device effect  does, in  
fact, meet the requirements for reporting; the sponsor- investigator will submit a completed  
FDA Form 3500A as soon as possible, but in no event later than 10 working days, after the determination  was made.  
 For each submitted FDA Form 3500A, the sponsor- investigator will identify all previously  
submitted reports that that addressed a similar adverse effect experience and will provide an  
analysis of the significance of newly reported adverse effect in light of any previous, similar report(s).  
 
Subsequent to the initial submission of a completed FDA Form 3500A, the sponsor- 
investigator will submit additional information  concerning the reported adverse  effect  as 
requested  by the FDA.  
 
Reporting  Process  
Unanticipated  Adverse  Device Effect reports  will be submitted  on FDA  Form  3500A. 
The contact  information  for submitting  reports  is: 
 Food and Drug  Administration  
Center  for Devices and  Radiological Health  
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 27 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   Document Mail Center - WO66 -G609 
10903 New  Hampshire Avenue 
Silver  Spring, Maryland  20993-0002 
 
Deviations from  the investigational plan.  
The sponsor-investigator shall notify Mayo IRB (see 21 CFR 56.108(a) (3) and (4)) of any deviation from the investigational plan to protect the life or physical well-being of a subject in an emergency. Such notice shall be given as soon as possible, but in no event later than 5 working days after  the emergency  occurred. Except in  such  an emergency,  prior approval by 
the sponsor-investigator is required for changes in or deviations from a plan, and if these changes or deviations may affect the scientific soundness of the plan or the rights, safety, or welfare of human subjects, FDA and IRB notification in accordance with 21 CFR 812.35(a) also is required. 
 
8.4 Stopping  Rules  
Study enrollment and  treatment  procedures will be  suspended in  the event:  
•  
• A participant experiences an SAE probably or definitely related to the study device or due 
participation  in the study. 
• The PI determines  that the study should be discontinued for any reason. 
 In the event  that the study enrollment is  suspended for any reason,  enrollment and  treatment  
would only be resumed after a thorough review of the incidents and any corrective and preventative actions have been put in place along with consultation between the study team and the IRB.  
 
8.5 Medical  Monitoring  
It is the responsibility of the sponsor-investigator to oversee the safety of the study. This  
safety  monitoring will include careful assessment and  appropriate reporting of adverse events  
as noted above, as well as the construction and implementation of a site data and safety- monitoring plan (see Section 10 Auditing, Monitoring and Inspecting). Medical monitoring  
will include a regular  assessment  of the number and type of serious adverse events.  
 
9 Data  Handling  and Record  Keeping  
9.1 Confidentiality  
Information about study subjects will be kept confidential and managed according to the requirements  of the Health  Insurance Portability  and Accountability  Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the following: 
• What  protected  health  information  (PHI)  will be collected  from  subjects  in this  study 
• Wh
o  will have access  to that information  and why  
• Who  will use or disclose that  information  
• The rights of a research subject  to revoke their authorization for use of their PHI.  
 In the event  that a subject  revokes authorization to  collect  or use PHI, the investigator,  by 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 28 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   regulation, retains the ability to use all information collected prior to the revocation of 
subject authorization. For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (long term survival status  that the  subject is  alive)  at the  end of their scheduled  study period. 
 
9.2 Source Documents  
Source data comprise all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
Source data are contained in source documents. Examples of these original documents, and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries  or evaluation  checklists, pharmacy  dispensing records, 
recorded data from automated instruments, copies or transcri ptions certified after verification  
as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and records kept at the pharmacy, at the laboratories, and at 
medico -technical departments involved in the clinical trial. When applicable, information  
recorded  on the CRF  shall match  the Source Data recorded on the Source Documents. 
 
9.3 Case  Report  Forms  
The study case report form (CRF) will be the primary data collection instrument for the  
study. All data requested on the CRF will be recorded, and all missing data explained as follows: 
 
• If a space on the CRF is left blank because the procedure was not done or the 
question was not asked, write  “N/D”.  
• If the item is  not applicable to the individual case, write “N/A”.  
• All entries  should be printed  legibly  in black ink. 
• If a data entry error is identified, it will be corrected by drawing a single straight line through the incorrect entry and the correct data will be entered above it. All such changes  will be  initialed  and dated. 
• Clarification of illegible or uncertain entries will be printed above the item, then  
initialed  and dated. 
 
Data  Management  
Study Source Data will be kept in  hard copy (where  applicable)  within  participant  case files,  
which will be kept in limited -access space reserved for study staff only. Electronic data will  
be managed  within  a password-protected study- specific internal database.  
 
Data  Processing  
Data will be processed within a study-specific Mayo Clinic internal database. Quality control will be applied  to each  stage  of data handling to ensure that  all data are reliable  and have 
been processed correctly. Original data will be preserved in such a way that any data  
transformed  during processing can be compared  to the original data.  
 
Data  Security  and Confidentiality  
The Mayo Clinic internal database system has built in systems for control of access, data integrity and audit trails. Access and confidentiality are controlled in a manner similar to  
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 29 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   other institutional systems.  
 
Data  Quality  Assurance  
A Quality Assurance audit may be conducted by the PI, or designee, at any time during or 
after this study. The audit may include, but not be limited to:  
 
• A review  of all ICFs  
• A review  of CRFs  and source documents 
• A review  of regulatory  documents 
• An assessment  of trial conduct and  compliance  
• And a review  of investigational device storage and accountability  records  
 
Data  Clarification  Process  
In response to a query on the part of the FDA, or in the event that the Mayo Clinic internal database program identifies a discrepancy, missing value, or other discrepancy in the CRF  
database,  the error  will be addressed  and a Data Clarification  Form  will be completed.  
 
9.4 Records  Retention  
The sponsor -investigator will maintain records and essential documents related to the  
conduct of the study. These will include subject  case histories  and regulatory documents. 
 The sponsor-investigator will retain the specified  records and  reports during the study and for 
the longer of the following;  
1. As outlined in  the Mayo  Clinic  Research  Policy Manual –“Retention  of and Access  to 
Research  Data Policy”  http://mayocontent.mayo.edu/research-policy/MSS_669717, 
 
OR 
 
2. A period of 2 years  after the latter  of the following two  dates:  The date on which  the 
investigation is terminated or completed, or the date that the records are no longer 
required for purposes of supporting a premarket approval application or a notice of completion  of a product development protocol. 
10 Study  Monitoring,  Auditing,  and Inspecting  
10.1 Study  Monitoring  Plan  
The investigator will allocate adequate time for such monitoring activities.  The Investigator  
will also  ensure that the monitor or other compliance or quality  assurance reviewer  is given 
access  to all the study- related  documents and  study related  facilities  (e.g. pharmacy,  
diagnostic laboratory, etc.), and has  adequate space to conduct the monitoring visit.  
 This study will be monitored on a routine basis during the conduct of the trial. The Mayo Clinic Office of Research Regulatory Support will assist the PI with monitoring of the trial.  
Clinical trial monitoring requires review of the study data generated from protocol activities  
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 30 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   to ensure the validity and integrity of the data while also protecting the rights and safety of 
study participants. They will also assist the PI with maintaining compliance to appropriate Food and Drug Administration regulations.  Medical safety monitoring will be conducted on an ongoing basis by an independent medical monitor, a physiatrist co -director of the Mayo Clinic Rehabilitation Medicine 
Research Center.  
 
10.2 Auditing  and Inspecting  
The sponsor- investigator will permit study -related monitoring, audits, and inspections by the 
IRB, the monitor, and government regulatory agencies, of all study related documents (e.g., source documents, regulatory documents, data collection instruments, study data etc.). The  
sponsor-investigator will ensure the capability for inspections of applicable study- related  
facilities  (e.g., pharmacy, diagnostic laboratory, etc.).  
 
Participation as a sponsor- investigator in this study implies acceptance of potential inspection  
by government regulatory authorities and applicable compliance offices.  
 
11 Ethical Considerations  
This study is to be conducted according to United States government regulations and 
Institutional research policies and procedures.  
 This protocol and any amendments will be submitted to a properly constituted local Institutional Review Board (IRB), in agreement with local legal prescriptions, for formal approval of the study. The decision of the IRB concerning the conduct of the study will be made in writing  to the sponsor-investigator before  commencement  of this study. 
 All subjects for this study will be provided a consent form describing this study and providing sufficient information for subjects to make an informed decision about their participation in this study.  This consent form will be submitted with the protocol for review 
and approval by the IRB for the study. The formal consent of a subject, using the Approved IRB consent form,  must be obtained before  that subject  undergoes any study procedure. The 
consent form must be signed and dated by the subject or the subj ect’s legally authorized  
representative,  and the individual obtaining the informed consent. 
 
12 Study  Finances  
12.1 Funding  Source  
This study will  be funded by the Mayo Clinic Center for Multiple Sclerosis and 
Autoimmune Neurology.  
12.2 Conflict  of Interest  
Any study team member who has a conflict of interest with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by a properly constituted Conflict of Interest Committee with a Committee -sanctioned  conflict management  plan that has been  reviewed  and approved by the 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 31 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   study sponsor-investigator prior to participation in this study. 
 
12.3 Subject  Stipends  or Payments  
Participants will be offered a $1,000 remuneration to be submitted at the end of the study. If they 
do not complete the study, they will be paid $55.55 per visit attended. They will also be offered parking passes for the Mayo Clinic lots on an ongoing basis. 
 
13 Publication  Plan  
The PI holds the primary responsibility for publication of the results of this study, deciding authorship, and finalizing the order of authorship. If multiple manuscripts result from the research,  authorship will be aligned with  individuals’ expertise and  career  objectives.  
Approval will be obtained from the  PI before any information related  to this study can be 
used or passed on to a third party. Once this study is approved, it will be registered to ClinicalTrials.gov.  
 
14 References  
1. Angeli, C. A., Edgerton, V. R., Gerasimenko, Y. P., et al., 2014. Altering spinal cord excitability enables voluntary movements after chronic complete paralysis in humans. Brain, 137(Pt 5), 1394-1409. doi:10.1093/brain/awu038 
2. Aslan, S. C., Legg Ditterline, B. E., Park, M. C., et al., 2018. Epidural Spinal Cord Stimulation of Lumbosacral Networks Modulates Arterial Blood Pressure in Individuals With Spinal Cord Injury- Induced Cardiovascular Deficits. Front Physiol, 9, 565. 
doi:10.3389/fphys.2018.00565 
3. Basmajian,  J. V., De Luca,  C. J. (1985). Muscles  Alive  : their functions revealed  by 
electromyography (5th ed.). Baltimore: Williams & Wilkins.  
4. Bohannon, R. W., Smith,  M. B., 1987. Interrater  reliability  of a modified  Ashworth scale 
of muscle  spasticity.  Phys Ther, 67(2), 206-207. doi:10.1093/ptj/67.2.206 
5. Calvert,  J. S., Grahn, P. J., Strommen,  J. A., et al., 2019. Electrophysiological Guidance 
of Epidural Electrode Array  Implantation  over the Human  Lumbosacral  Spinal Cord  to 
Enable Motor Function after Chronic Paralysis. J Neurotrauma, 36(9), 1451-1460. doi:10.1089/neu.2018.5921 
6. Chou, L.  S., Kaufman,  K. R., Brey,  R. H., et al.,  2001. Motion of the whole body's center 
of mass when stepping over obstacles of different heights. Gait Posture, 13(1), 17-26. doi:10.1016/s0966-6362(00)00087-4 
7. Cogan, S. F., Ludwig, K. A., Welle, C. G., & Takmakov, P., 2016. Tissue damage thresholds during therapeutic electrical stimulation. Journal of neural engineering, 13(2), 021001. https://doi.org/10.1088/1741-2560/13/2/021001 
8. Fischer, J. S., LaRocca, N. G., Miller, D. M., et al., 1999. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler, 5(4), 251-259. doi:10.1177/135245859900500410 
9. G
erasimenko, Y. P., Lu, D. C., Modaber, M., et al., 2015. Noninvasive Reactivation of 
Motor Descending Control after Paralysis. J Neurotrauma, 32(24), 1968-1980. doi:10.1089/neu.2015.4008 
10. Gill, M., Linde, M., Fautsch, K., et al., 2020. Epidural Electrical Stimulation of the Lumbosacral  Spinal Cord Improves Trunk Stability  During Seated  Reaching  in Two 
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 32 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   Humans With Severe Thoracic Spinal Cord Injury. Front Syst Neurosci, 14, 79. 
doi:10.3389/fnsys.2020.569337 
11. Gill, M. L., Grahn, P.  J., Calvert,  J. S., et al., 2018. Neuromodulation of lumbosacral  
spinal networks enables independent stepping after complete paraplegia. Nat Med, 24(11),  1677-1682. doi:10.1038/s41591-018-0175-7 
12. Grahn, P. J., Lavrov, I. A., Sayenko, D. G., et al., 2017. Enabling Task- Specific 
Volitional Motor Functions via Spinal Cord Neuromodulation in a Human With Paraplegia.  Mayo  Clin Proc,  92(4),  544-554. doi:10.1016/j.mayocp.2017.02.014 
13. Harkema, S., Gerasimenko, Y., Hodes, J., et al., 2011. Effect of epidural stimulation of  
the lumbosacral  spinal cord  on voluntary movement, standing, and  assisted  stepping after  
motor complete paraplegia: a case study. Lancet, 377(9781), 1938-1947. doi:10.1016/S0140-6736(11)60547-3 
14. Harkema, S. J., Legg Ditterline, B., Wang, S., et al., 2018. Epidural Spinal Cord Stimulation  Training and Sustained  Recovery  of Cardiovascular Function in Individuals 
With Chronic Cervical Spinal Cord Injury. JAMA Neurol, 75(12), 1569-1571. 
doi:10.1001/jamaneurol.2018.2617 
15. Harkema,  S. J., Wang,  S., Angeli, C.  A., et al., 2018. Normalization  of Blood Pressure  
With Spinal Cord Epidural Stimulation After Severe Spinal Cord Injury. Front Hum Neurosci,  12, 83. doi:10.3389/fnhum.2018.00083 
16. Herrity, A. N., Williams, C. S., Angeli, C. A., et al., 2018. Lumbosacral spinal cord epidural stimulation improves voiding function after human spinal cord injury. Sci Rep,  
8(1),  8688. doi:10.1038/s41598-018-26602-2 
17. Kassa, R. M., Sechi, E., Flanagan, E. P., et al., 2021. Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Mult  
Scler,  27(6), 895-902. doi:10.1177/1352458520940983 
18. Keegan, B. M., Kaufmann, T. J., Weinshenker, B. G., et al., 2018. Progressive motor impairment from a critically located lesion in highly restricted CNS -demyelinating  
disease.  Mult Scler, 24 (11),  1445-1452. doi:10.1177/1352458518781979 
19. Kreydin, E., Zhong, H., Latack, K., et al., 2020. Transcutaneous Electrical Spinal Cord Neuromodulator (TESCoN) Improves Symptoms of Overactive Bladder. Front Syst Neurosci,  14, 1. doi:10.3389/fnsys.2020.00001 
20. Lu, D. C., Edgerton, V. R., Modaber, M., et al., 2016. Engaging Cervical Spinal Cord Networks to Reenable Volitional Control of Hand Function in Tetraplegic Patients. Neurorehabil Neural Repair, 30(10),  951-962. doi:10.1177/1545968316644344 
21. Mccreery, Douglas & Agnew, William & Yuen, Ted & Bullara, Leo., 1990. Charge density and charge per phase as cofactors in neural injury induced by electrical stimulation. Biomedical Engineering, IEEE Transactions on. 37, 996 - 1001. 10.1109/10.102812 
22. Podsiadlo, D., Richardson, S., 1991. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc, 39(2), 142-148. doi:10.1111/j.1532- 5415.1991.tb01616.x 
23. Rejc, E., Angeli, C., Harkema, S., 2015. Effects of Lumbosacral Spinal Cord Epidural Stimulation  for Standing after Chronic Complete Paralysis  in Humans. PLoS  One,  10(7),  
e0133998. doi:10.1371/journal.pone.0133998 
24. Rejc, E., Angeli, C. A., Bryant, N., et al., 2017. Effects of Stand and Step Training with Epidural Stimulation  on Motor Function for Standing in  Chronic Complete  Paraplegics.  J 
Neurotrauma, 34(9), 1787-1802. doi:10.1089/neu.2016.4516 
25. R
oberts, B. W. R., Atkinson, D. A., Manson, G. A., et al., 2021. Transcutaneous spinal  
  ES in MS   Version 2.2 
  Revised 06/23/2023 
Page 33 of 33 
Kristin D. Zhao, Ph.D.                                                                                                                                                       CONFIDENTIAL   cord stimulation improves postural stability in individuals with multiple sclerosis. Mult  
Scler  Relat Disord, 52, 103009. doi:10.1016/j.msard.2021.103009 
26. Rudick, R., Antel,  J., Confavreux, C., et al.,  1997. Recommendations from  the National  
Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol, 
42(3),  379-382. doi:10.1002/ana.410420318 
27. Schwid, S. R., Goodman, A. D., Mattson, D. H., et al., 1997. The measurement of ambulatory impairment in multiple sclerosis. Neurology, 49(5), 1419-1424. doi:10.1212/wnl.49.5.1419 
28. Sechi, E., Keegan, B. M., Kaufmann, T. J., et al., 2019. Unilateral motor progression in MS: Association with a critical corticospinal tract lesion. Neurology, 93(7), e628-e634. doi:10.1212/WNL.0000000000007944 
29. Smith, A. W., Kirtley, C., Jamshidi, M., 2000. Intrarater reliability of manual passive  
movement velocity  in the clinical  evaluation  of knee  extensor muscle  tone. Arch  Phys  
Med Rehabil, 81(10), 1428-1431. doi:10.1053/apmr.2000.9399 
30. Thompson, A. J., Banwell, B. L., Barkhof, F., et al., 2018. Diagnosis of multiple sclerosis:  2017 revisions of the McDonald  criteria. Lancet  Neurol, 17(2),  162-173. 
doi:10.1016/S1474-4422(17)30470-2 
31. Wagner, F. B., Mignardot, J. B., Le Goff-Mignardot, C. G., et al., 2018. Targeted neurotechnology restores walking  in humans with spinal cord injury. Nature, 563(7729), 
65-71. doi:10.1038/s41586-018-0649-2 
32. Wartenberg,  R., 1951. Pendulousness of the legs as a diagnostic test. Neurology, 1(1), 18- 
24. doi:10.1212/wnl.1.1.18 
33. West, C. R., Phillips, A. A., Squair, J. W., et al., 2018. Association of Epidural Stimulation  With  Cardiovascular  Function in an Individual With  Spinal Cord  Injury. 
JAMA  Neurol, 75(5), 630-632. doi:10.1001/jamaneurol.2017.5055 
34. Whelan, A., Sexton, A., Jones, M., et al., 2018. Predictive value of the pendulum test for assessing knee extensor spasticity. J Neuroeng Rehabil, 15(1), 68. doi:10.1186/s12984- 018-0411-x 